A NEW visual impairment
treatment for people with diabetes
has been launched in the UK,
Lucentis(R) (ranibizumab).
The drug is the first licensed
therapy to improve vision and
vision-related quality of life in
people with visual impairment due
to diabetic macular oedema.
“Ranibizumab has the potential
to transform the way we treat
DMO,” said Nicholas Beare,
Consultant Ophthalmologist at
Royal Liverpool University Hospital.
“For the last 25 years, laser therapy
has been the standard treatment
for DMO but it is not generally
associated with visual improvement,
whereas ranibizumab has been
shown to produce a rapid and
sustained improvement in vision.”The above article was sent to subscribers in Pharmacy Daily's issue from 14 Jan 11 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 14 Jan 11
MAYNE Pharma Group Limited has filed a patent infringement suit against Sun Pharmaceutical Industries Ltd and Inc., in the United States District Court, according to yesterday’s ASX announcement.
PHARMACY Connect 2024 conference will feature a provocative ‘Great Debate’ during the Harm Minimisation Workshop on Thu 05 Sep at the Hyatt Regency in Sydney.
LTR Pharma Limited has successfully raised $10.5 million through a share placement to sophisticated and new institutional investors, significantly surpassing initial demand.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.